John Strafford

John has 14 years of business development and strategic consulting experience in the biopharma industry. Since joining Silence in 2018, John has led the formation of collaborations with AstraZeneca, Mallinckrodt, and Takeda as well as a range of undisclosed research collaborations in support of the extra-hepatic delivery strategy. Together, these collaborations have delivered over $100 million in upfront payments and represent a total potential deal value of over $6 billion. Before joining Silence, John held positions of increasing responsibility at Antisoma, Easton Associates, Novasecta, and Concordia International.

John holds a Ph.D. in Biochemical Engineering from University College London, an MRes in Bioinformatics from the University of York, and a BSc in Molecular Biology from the University of Edinburgh. In 2009 John was awarded the Pharma Licensing Group (PLG) Business Development Best Newcomer of the Year Award.